Clinical Trials Sponsored by Synthon BV

Total 432 results

ExeVir Bio BV

Terminated

Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19

Covid19

Italy, Belgium, Moldova, Republic of
Acerta Pharma BV

Completed

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Healthy Participants

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Acerta Pharma BV

Completed

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Rheumatoid Arthritis

United States
Crucell Holland BV

Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United Kingdom
Delta Crystallon BV

Completed

A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis

Multiple Sclerosis

Bulgaria
Crucell Holland BV

Completed

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Influenza

Belgium
Crucell Holland BV

Completed

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Crucell Holland BV

Completed

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies

India
Crucell Holland BV

Completed

Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents

Rabies

Philippines
Glycostem Therapeutics BV

Recruiting

Registry of Patients Having Received oNKord®

AML

Switzerland, Germany
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Calypso Biotech BV

Completed

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Celiac Disease | Eosinophilic Esophagitis

Netherlands, Belgium, Finland, Germany, Norway
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
Caelus Pharmaceuticals BV

Completed

Intestinimonas for Prevention of Type 2 Diabetes Mellitus

PreDiabetes

Italy
Rosesta Medical BV

Completed

FERTI-LILY Safety Study

Safety Issues | Natural Conception | Label Comprehension | Device Usability

United States
Staten Biotechnology BV

Terminated

A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Hypertriglyceridemia

United Kingdom
Audion Therapeutics BV

Withdrawn

A Trial of LY3056480 in Patients With SNLH (VESTA)

Sensorineural Hearing Loss

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Healthy Volunteers

United States
Fontem Ventures BV

Completed

A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Hepatic Insufficiency

United States
Acerta Pharma BV

Terminated

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Crucell Holland BV

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Healthy Participants

United States
Crucell Holland BV

Completed

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Influenza

Belgium
Crucell Holland BV

Completed

A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Infections

Philippines
Crucell Holland BV

Completed

Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V

Influenza

Italy
Crucell Holland BV

Completed

Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children

Influenza

China
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children

Hepatitis A

India
Crucell Holland BV

Completed

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers

Influenza

Switzerland
Crucell Holland BV

Completed

Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Infections

Philippines
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

Influenza

Switzerland
Crucell Holland BV

Completed

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

Rabies

United States
Synchron Medical, Inc.

Withdrawn

SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Paralysis | Amyotrophic Lateral Sclerosis | Muscular Dystrophies | Neurologic Disorder | Spinal Muscular Atrophy | Spinal Cord Injury | Stroke, Lacunar | Upper Limb Injury | Paralysis; Stroke | Stroke, Brainstem

Australia
Synthes GmbH
Synthes Asia Pacific

Completed

Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures

Tibial Fractures

China, Australia, Netherlands, Norway
Synchron Medical, Inc.

Active, not recruiting

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Paralysis | Amyotrophic Lateral Sclerosis | Muscular Dystrophies | Spinal Cord Injuries | Neurologic Disorder | Spinal Muscular Atrophy | Cervical Spinal Cord Injury | Stroke, Lacunar | Paralysis; Stroke | Stroke Brainstem | Tetraplegic; Paralysis | Quadriplegia/Tetraplegia

United States
Radboud University Medical Center
Sorgente BV; Fresenius Kabi Nederland BV

Completed

Normalcy of Food Intake in Head and Neck Cancer Patients (FOCISD)

Neoplasms, Head and Neck

Netherlands
CoreAalst BV
Hexacath, France

Recruiting

The Euro-CRAFT Registry (Euro-CRAFT)

Coronary Microvascular Disease

Netherlands, Belgium, Spain
moveUP bv
Firstkind Ltd

Recruiting

The Post-operative Effect on Formation of Oedema After Total Knee Arthroplasty With or Without the Use of a Nerve Stimulator (the gekoTM Device)

Joint Diseases | Osteoarthritis, Knee | Rehabilitation | Edema Leg

Belgium
Khondrion BV
Julius Clinical

Completed

The KHENERGYZE Study

Mitochondrial Diseases | Mitochondrial Myopathies | MELAS Syndrome | Mitochondrial Encephalomyopathies | MIDD

Netherlands, Denmark, Germany, United Kingdom
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
Cardiac Research Institute BV

Completed

Microcirculatory Status After Intravascular Lithotripsy (MARVEL)

Coronary Artery Disease | Chronic Coronary Insufficiency

Spain
AstraZeneca
Acerta Pharma BV

Completed

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Infectious Disease

United States

3

Subscribe